search
Back to results

Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section

Primary Purpose

Hemorrhage of Cesarean Section and/or Perineal Wound, Postpartum Hemorrhage, Uterine Atony

Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Tranexamic Acid
Intraoperative Uterine Cooling
Sponsored by
Talkha Central Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hemorrhage of Cesarean Section and/or Perineal Wound focused on measuring Caesarean Section, Tranexamic Acid, Postpartum Hemorrhage, Ecbolics

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Women who attended Talkha Central Hospital for planned or emergency secondary CS.
  • Singleton pregnancy at term with gestational age (G.A) between 38±5 and 40 weeks.

Exclusion Criteria:

  • Preoperative exclusion criteria were women who had any disorders of heart, liver, kidney, brain or blood, Abruptio placenta, placental abnormalities or accrete syndromes, Polyhydramnios, macrosomia, preeclampsia, allergy to TXA, history of thromboembolic disorders, or severe anemia.
  • Intraoperative exclusion criteria was inability to exteriorize the uterus during CS for group (Y).

Sites / Locations

  • Talkha Central Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Group (X) Prophylactic Tranexamic Acid

Group (Y) Intraoperative Uterine Cooling

Arm Description

Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).

Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly [Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen].

Outcomes

Primary Outcome Measures

Total blood loss volume
Estimation of Total Blood Loss Volume (ml) during CS and in the PACU.

Secondary Outcome Measures

Hematocrit value (Hct)
Estimating change in Pre- versus Post-operative hematocrit values (%) at 6 hours postoperatively.
Overall blood loss volume greater than 1000 cc
Estimation of overall blood loss volume during CS and up to 6 hours postoperatively
Need for Additional Ecbolics
Need for additional ecbolics to arrest and manage bleeding if there is a uterine atony
Need for other surgical measures to stop bleeding
Need for other surgical measures to stop bleeding (B-lynch denoting uterine atony, uterine artery ligation, hysterectomy)
Transfusion of Blood or Blood Products
Need for transfusion of blood or blood products during CS and in the PACU

Full Information

First Posted
May 19, 2016
Last Updated
September 1, 2016
Sponsor
Talkha Central Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02780245
Brief Title
Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section
Official Title
Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
June 2016 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Talkha Central Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to compare role of a prophylactic predefined intravenous Tranexamic Acid dose versus intraoperative Uterine Cooling in reducing blood loss and incidence of postpartum hemorrhage at secondary CS.
Detailed Description
Bleeding during vaginal or operative delivery is always of prime concern. Despite significant progress in obstetric care 125,000 women die from obstetric hemorrhage annually in the world. The incidence of CS is increasing, and the average blood loss during CS (1000 mL) is double the amount lost during vaginal delivery (500 mL). CS rate as high as 25-30% in many areas of the world. In Egypt the CS rate is 27.6 %, in United States of America, from 1970-2009 the CS rate rose from 4.5-32.9%, and declined to 32.8% of all deliveries at 2010. In spite of the various measures to prevent blood loss during and after CS, post-partum hemorrhage (PPH) continues to be the most common complication seen in almost 20% of the cases, and causes approximately 25% of maternal deaths worldwide, leading to increased maternal morbidity and mortality. Women who undergo a CS are much more likely to be delivered by a repeat operation in subsequent pregnancies. For women undergoing subsequent CS, the maternal risks are even greater like massive obstetric hemorrhage, hysterectomy, admission to an intensive care unit, or maternal death. Medications, such as oxytocin, misoprostol and prostaglandin F2α, have been used to control bleeding postoperatively. TXA is a synthetic analog of the amino acid lysine, as an antifibrinolytic agent. Its intravenous administration has been routinely used for many years to reduce or prevent excessive hemorrhage in various medical conditions or disorders (helping hemostasis), also during and after surgical procedures like benign hysterectomy, open heart surgeries, scoliosis surgery, oral surgery, liver surgeries, total hip or knee arthroplasty, and urology. It has been shown to be very useful and efficient in reducing blood loss and incidence of blood transfusion in these surgeries, and decreases the risk of death in bleeding trauma patients. It was also included in the World Health Organization (WHO) Model List of Essential Medicines. About its role in CS, some recent studies showed that TXA has advantage and useful effect safely in reducing blood loss and requirement of additional ecbolics. Its doses used intravenously to reduce blood loss at CS were a bolus of 1gm, 10 mg/kg , or 15 mg/kg which had an advantage over 10 mg/kg in anemic parturients. A recent study by Mitchell et al. concluded that Uterine cooling during cesarean delivery was efficient enough to decrease blood loss and the incidence of postpartum hemorrhage. This study aims to compare role of a prophylactic predefined intravenous Tranexamic Acid dose versus intraoperative Uterine Cooling in reducing blood loss and incidence of postpartum hemorrhage at secondary CS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhage of Cesarean Section and/or Perineal Wound, Postpartum Hemorrhage, Uterine Atony
Keywords
Caesarean Section, Tranexamic Acid, Postpartum Hemorrhage, Ecbolics

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group (X) Prophylactic Tranexamic Acid
Arm Type
Experimental
Arm Description
Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).
Arm Title
Group (Y) Intraoperative Uterine Cooling
Arm Type
Experimental
Arm Description
Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly [Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen].
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Other Intervention Name(s)
TXA
Intervention Description
At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
Intervention Type
Procedure
Intervention Name(s)
Intraoperative Uterine Cooling
Intervention Description
Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
Primary Outcome Measure Information:
Title
Total blood loss volume
Description
Estimation of Total Blood Loss Volume (ml) during CS and in the PACU.
Time Frame
Up to 3 hours
Secondary Outcome Measure Information:
Title
Hematocrit value (Hct)
Description
Estimating change in Pre- versus Post-operative hematocrit values (%) at 6 hours postoperatively.
Time Frame
6 hours postoperative period
Title
Overall blood loss volume greater than 1000 cc
Description
Estimation of overall blood loss volume during CS and up to 6 hours postoperatively
Time Frame
Up to 9 hours
Title
Need for Additional Ecbolics
Description
Need for additional ecbolics to arrest and manage bleeding if there is a uterine atony
Time Frame
Intraoperative
Title
Need for other surgical measures to stop bleeding
Description
Need for other surgical measures to stop bleeding (B-lynch denoting uterine atony, uterine artery ligation, hysterectomy)
Time Frame
Intraoperative
Title
Transfusion of Blood or Blood Products
Description
Need for transfusion of blood or blood products during CS and in the PACU
Time Frame
Up to 3 hours
Other Pre-specified Outcome Measures:
Title
Blood Pressure
Description
Measuring maternal blood pressure (mmHg) immediately postoperative and after 3 hours postoperative.
Time Frame
Up to 3 hours
Title
Maternal Side effects of intervention administered
Description
Recording any Maternal side effects of interventions administered
Time Frame
Up to 9 hours
Title
APGAR Scores
Description
Recording of APGAR Score (/10) for all neonates immediately after delivery
Time Frame
up to 2 hours
Title
Pulse Rate
Description
Measuring maternal pulse rate (/minute) immediately postoperative and after 3 hours postoperative.
Time Frame
Up to 3 hours

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women who attended Talkha Central Hospital for planned or emergency secondary CS. Singleton pregnancy at term with gestational age (G.A) between 38±5 and 40 weeks. Exclusion Criteria: Preoperative exclusion criteria were women who had any disorders of heart, liver, kidney, brain or blood, Abruptio placenta, placental abnormalities or accrete syndromes, Polyhydramnios, macrosomia, preeclampsia, allergy to TXA, history of thromboembolic disorders, or severe anemia. Intraoperative exclusion criteria was inability to exteriorize the uterus during CS for group (Y).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amro M Hetta, M.B., Ch.B.
Organizational Affiliation
Talkha Central Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Talkha Central Hospital
City
Mansoura
State/Province
Al-Dakahliya
ZIP/Postal Code
35511
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
Citation
Tarabrin O, Kaminskiy V, Galich S, Tkachenko R, Gulyaev A, Shcherbakov S, et al. Efficacy of tranexamic acid in decreasing blood loss during cesarean section. Critical Care 2012, 16(1): 1-189.
Results Reference
background
PubMed Identifier
25068947
Citation
Ahmed MR, Sayed Ahmed WA, Madny EH, Arafa AM, Said MM. Efficacy of tranexamic acid in decreasing blood loss in elective caesarean delivery. J Matern Fetal Neonatal Med. 2015 Jun;28(9):1014-8. doi: 10.3109/14767058.2014.941283. Epub 2014 Jul 28.
Results Reference
background
Citation
Gibbons L, Belizán JM, Lauer JA, Betrán AP, Merialdi M, Althabe F. The global numbers and costs of additionally needed and unnecessary caesarean sections performed per year: overuse as a barrier to universal coverage. World health report 2010, 30: 1-31.
Results Reference
background
PubMed Identifier
24974589
Citation
Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Wilson EC, Mathews TJ. Births: final data for 2010. Natl Vital Stat Rep. 2012 Aug 28;61(1):1-72.
Results Reference
background
Citation
Mayur G, Purvi P, Ashoo G, Pankaj D. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: a randomized case controlled prospective study. J Obstet Gynecol India 2007, 57(3): 4.
Results Reference
background
PubMed Identifier
23586122
Citation
WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2012. Available from http://www.ncbi.nlm.nih.gov/books/NBK131942/
Results Reference
background
PubMed Identifier
16846571
Citation
Cahill AG, Stamilio DM, Odibo AO, Peipert JF, Ratcliffe SJ, Stevens EJ, Sammel MD, Macones GA. Is vaginal birth after cesarean (VBAC) or elective repeat cesarean safer in women with a prior vaginal delivery? Am J Obstet Gynecol. 2006 Oct;195(4):1143-7. doi: 10.1016/j.ajog.2006.06.045. Epub 2006 Jul 17.
Results Reference
background
PubMed Identifier
22071057
Citation
Marshall NE, Fu R, Guise JM. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol. 2011 Sep;205(3):262.e1-8. doi: 10.1016/j.ajog.2011.06.035. Epub 2011 Jun 15.
Results Reference
background
PubMed Identifier
16738145
Citation
Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai B, Langer O, Thorp JM, Ramin SM, Mercer BM; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006 Jun;107(6):1226-32. doi: 10.1097/01.AOG.0000219750.79480.84.
Results Reference
background
PubMed Identifier
23823946
Citation
Shahid A, Khan A. Tranexamic acid in decreasing blood loss during and after caesarean section. J Coll Physicians Surg Pak. 2013 Jul;23(7):459-62.
Results Reference
background
PubMed Identifier
25571934
Citation
Sentilhes L, Lasocki S, Ducloy-Bouthors AS, Deruelle P, Dreyfus M, Perrotin F, Goffinet F, Deneux-Tharaux C. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. Br J Anaesth. 2015 Apr;114(4):576-87. doi: 10.1093/bja/aeu448. Epub 2015 Jan 8.
Results Reference
background
PubMed Identifier
26760392
Citation
Gaines-Dillard N, Bartley MK, Rosini JM. Tranexamic acid in the trauma patient. Nursing. 2016 Feb;46(2):60-2. doi: 10.1097/01.NURSE.0000476234.78599.e2. No abstract available.
Results Reference
background
Citation
Yehia AH, Koleib MH, Abdelazim IA, Atik A. Tranexamic acid reduces blood loss during and after cesarean section: A double blinded, randomized, controlled trial. Asian Pacific Journal of Reproduction 2014, 3(1): 53-56.
Results Reference
background
PubMed Identifier
26829509
Citation
Topsoee MF, Bergholt T, Ravn P, Schouenborg L, Moeller C, Ottesen B, Settnes A. Anti-hemorrhagic effect of prophylactic tranexamic acid in benign hysterectomy-a double-blinded randomized placebo-controlled trial. Am J Obstet Gynecol. 2016 Jul;215(1):72.e1-8. doi: 10.1016/j.ajog.2016.01.184. Epub 2016 Jan 30.
Results Reference
background
PubMed Identifier
20554319
Citation
CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.
Results Reference
background
PubMed Identifier
21872857
Citation
Movafegh A, Eslamian L, Dorabadi A. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet. 2011 Dec;115(3):224-6. doi: 10.1016/j.ijgo.2011.07.015. Epub 2011 Aug 27.
Results Reference
background
PubMed Identifier
26952346
Citation
Sujata N, Tobin R, Kaur R, Aneja A, Khanna M, Hanjoora VM. Randomized controlled trial of tranexamic acid among parturients at increased risk for postpartum hemorrhage undergoing cesarean delivery. Int J Gynaecol Obstet. 2016 Jun;133(3):312-5. doi: 10.1016/j.ijgo.2015.09.032. Epub 2016 Feb 16.
Results Reference
background
PubMed Identifier
26341174
Citation
Maged AM, Helal OM, Elsherbini MM, Eid MM, Elkomy RO, Dahab S, Elsissy MH. A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery. Int J Gynaecol Obstet. 2015 Dec;131(3):265-8. doi: 10.1016/j.ijgo.2015.05.027. Epub 2015 Aug 15.
Results Reference
background
PubMed Identifier
26226243
Citation
Wang HY, Hong SK, Duan Y, Yin HM. Tranexamic acid and blood loss during and after cesarean section: a meta-analysis. J Perinatol. 2015 Oct;35(10):818-25. doi: 10.1038/jp.2015.93. Epub 2015 Jul 30.
Results Reference
background
PubMed Identifier
26698831
Citation
Simonazzi G, Bisulli M, Saccone G, Moro E, Marshall A, Berghella V. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand. 2016 Jan;95(1):28-37. doi: 10.1111/aogs.12798. Epub 2015 Nov 12.
Results Reference
background
Citation
Gupta A, Dwivedi Y, Shakya V, Srivastva U, Saxena A, Agarwal AM, et al. Efficacy of Tranexamic Acid in Reducing Perioperative Blood Loss During Caesarean Section: A Placebo Controlled Double Blind Study. International Journal of Scientific Research 2016, 5(3).
Results Reference
background
PubMed Identifier
20979013
Citation
Gungorduk K, Yildirim G, Asicioglu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol. 2011 Mar;28(3):233-40. doi: 10.1055/s-0030-1268238. Epub 2010 Oct 26.
Results Reference
background
PubMed Identifier
24348295
Citation
Goswami U, Sarangi S, Gupta S, Babbar S. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: A double-blind randomized case control prospective trial. Saudi J Anaesth. 2013 Oct;7(4):427-31. doi: 10.4103/1658-354X.121077.
Results Reference
background
PubMed Identifier
14746950
Citation
Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol. 2004 Feb 10;112(2):154-7. doi: 10.1016/s0301-2115(03)00287-2.
Results Reference
background
PubMed Identifier
19165682
Citation
Sekhavat L, Tabatabaii A, Dalili M, Farajkhoda T, Tafti AD. Efficacy of tranexamic acid in reducing blood loss after cesarean section. J Matern Fetal Neonatal Med. 2009 Jan;22(1):72-5. doi: 10.1080/14767050802353580.
Results Reference
background
Citation
Mitchell JL, Stecher J, Crowson J, Rich D. Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage: A Randomized Controlled Trial [31]. Obstetrics & Gynecology. 2015 May 1;125:9S-10S.
Results Reference
background

Learn more about this trial

Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section

We'll reach out to this number within 24 hrs